Oncology Continuing Education

Stay Informed While Earning Oncology CME Credits

The cancer treatment landscape is rapidly changing with new discoveries and expert guidance emerging. As research, testing and treatment strategies continue to evolve, clinicians must keep abreast of the latest data on molecular mechanisms, emerging therapies, current standards of care, expert guideline updates, and new strategies for treatment. Whether you are looking for education on the value and interpretation of real-world evidence for clinical decision making, translation of efficacy and safety of therapeutic agents to decisions for your patients, or resources to share with patients and families navigating their cancer journey, you’ll find educational activities and resources here to help improve your knowledge and help your patients better take part in their care.

Our activities offer many credit types, including CME, AAFP Prescribed Credit, CNE, CPE, ABIM MOC, and ABP MOC. Each activity has been designed to meet the requirements for CME for MIPS. See each activity’s information page for the exact credit type and amount of credit offered.

Jump to:


Live & On-Demand Webcasts BriefCases CMEOCast Animations Patient Resources


Combos are Complicated! Navigating the Balance of Efficacy and Safety in Advanced Endometrial Cancer



Register Now  

Live Webcast | Thursday, December 2, 2021 | 12:00 PM – 1:30 PM ET

This CMEO Live and OnDemand will provide learners with the rationale and data for new combination therapies approved for advanced EC as well as best practices to improve patient adherence to their regimens, with the goal of early recognition and appropriate management of AEs.

The Role of Antibody Drug Conjugates in Advanced Non-Small Cell Lung Cancer: Guidance for Today and the Path Forward


Participate Now  

The discovery of molecular alterations that drive tumor initiation and progression has revolutionized the treatment strategy for non-small cell lung cancer (NSCLC) by matching targeted therapies to a specific mutation, leading to significantly improved therapeutic efficacy. However, despite the initial effectiveness of targeted therapy for NSCLC, most patients ultimately develop acquired resistance with subsequent disease progression, making it imperative for clinicians to receive up-to-date education on evaluating new therapeutic options to improve outcomes and better tailor treatment strategies.

In this CME Outfitters OnDemand, integrations of animated 3-D models will provide visual representation of the mechanisms and characteristics of antibody drug conjugates (ADCs) in NSCLC to complement expert faculty insights and evidence supporting testing strategies to identify predictive biomarkers, emerging treatment options for advanced or metastatic NSCLC, and best practices for managing patients with lung cancer in the face of COVID-19 and beyond.

Cutting Through Comorbidities: Clearing the Way to Appropriate Anticoagulant Therapy in Patients at Risk for Deep Vein Thrombosis and Pulmonary Embolism


Participate Now  

In this CME Outfitters BriefCase you will meet Walter, a 71-year-old African-American male who presents to his primary care physician’s office with swelling in his right leg. Expert faculty will assess the common comorbidities and discuss applying anticoagulant strategies that reflect randomized controlled trials (RCTs), real-world data, and individual patient characteristics.

Addressing Disparities in Care: Assessing Patient Characteristics When Determining Next Steps for Anticoagulant Treatment Selection


Participate Now  

The second installment of this CME Outfitters BriefCase series introduces Gordon, a 67-year-old Black man who complains of recent pain and swelling in his right leg, and explores this case with a focus on the impact of racial and ethnic disparities on the care of individuals who are candidates for anticoagulation therapy, and applying patient selection criteria for anticoagulation treatment that minimizes disparities and unconscious bias to optimize patient outcomes.

Management of Patients with Metastatic Castration-Sensitive Prostrate Cancer


Participate Now  

In this CME Outfitters podcast, expert faculty focus on patient selection criteria for second-generation antiandrogen therapy and the role of molecular testing risk stratification of patients with metastatic CSPC.

Sorting Out the Androgen Deprivation Therapy Options for Locally Advanced CSPC


Participate Now  

Despite the development of investigational and therapeutic options for prostate cancer, a lack of consensus among clinicians regarding patient management in early disease stages remains. Patients with locally advanced or metastatic castration-sensitive prostate cancer should receive androgen deprivation therapy (ADT) after definitive therapy, and it is imperative that clinicians consider luteinizing hormone releasing hormone (LHRH) antagonists in patients with major adverse cardiovascular events (MACE) risk factors. Additionally, must weigh factors that might negatively impact ADT adherence against the choice of ADT. This CMEOCast episode will aim to improve knowledge and competence in integrating the latest data on the management of patients with early-stage prostate cancer by evaluating strategies for its management and differentiating the potential for adverse effects between androgen deprivation therapies

Treatment Options and Clinical Dilemmas in Biochemical Recurrence


Participate Now  

This CME Outfitters podcast will focus on how clinicians can individualize treatment decisions, based on the use of risk assessment algorithms and advanced imaging techniques with greater ability to detect the sites and extent of disease at BCR. These tools have already demonstrated the ability to change treatment decisions and will substantially impact the management of patients with BCR after radical prostatectomy.

Disease States and Staging of Castration-Sensitive Prostate Cancer


Participate Now  

The first episode of this CME Outfitters podcast series on castration-sensitive prostate cancer (CSPC) will outline the current state of staging in CSPC and clarify the findings of reports detailing the pathology of prostate cancer specimens.

Real-World Data for Real-World Patients: A Broadened Lens to Informed Decision-Making in Venous Thromboembolism


Participate Now  

This CMEOCast podcast will compare the safety and efficacy of DOACs versus VKAs based on RWD, its methodology, study design, and assessment considerations, and focus on integrating this data into practice to individualize treatment decision-making for patients with VTE.

Maintenance Therapy in Metastatic Urothelial Carcinoma (mUC): Integrating Current Treatment Options into Practice


Participate Now  

The first episode of this CMEOCast podcast series on practice-changing treatment advances in mUC focuses on examining current 1L treatment options, including maintenance therapy to optimize patient outcomes in mUC.

Treatment and Sequencing Strategies: Providing the Best Care for Patients with Metastatic Urothelial Carcinoma (mUC)


Participate Now  

This CMEOCast podcast features expert faculty evaluating efficacy data for 1L and 2L sequencing strategies in patients with mUC highighting immune checkpoint inhibitors and other novel agents, as well as provide strategies for managing adverse events during treatment.

Informed Decisions: Sharing Safety and Efficacy Data with Patients with Metastatic Urothelial Carcinoma (mUC)


Participate Now  

The final episode of this CMEOCast podcast series on providing the best care for patients with mUC focuses on helping clinicians stay abreast of the evolving evidence for maintenance immunotherapy regimens, providing patients with education that will empower them to be stakeholders in their care, and considering patient perspectives and preferences as a part of shared decision-making, in order to choose the optimal evidence-based course of treatment.


The Role of Antibody Drug Conjugates in Advanced Non-Small Cell Lung Cancer: 3D Animation

View this animation to understand the mechanisms and characteristics of antibody drug conjugates (ADCs) in NSCLC

Whiteboard Animation: Real-World Evidence in Metastatic Breast Cancer

In oncology, real-world evidence, or RWE, refers to evidence derived from the use and analysis of real-world data, or RWD, which are data obtained outside the context of randomized controlled trials, or RCTs. View this animation to learn more about RWE in Metastatic Breast Cancer.

Patient Resources

You may have a million questions about bladder cancer, but where do you to start? CME Outfitters talked with patients and caregivers to find out what information was useful for them and what questions they asked their physician and care team during visits. We compiled resources and questions to ask that we hope will be helpful as you and your family navigate this journey.

What You Need to Know to Share the Metastatic Urothelial Carcinoma (mUC) Decision-Making with Your Physician

What Questions Should I Be Asking About My Bladder Cancer?

You may have a million questions, but where do you to start? CME Outfitters talked with patients and caregivers to find out what questions they asked their physician and care team during visits. Here are some questions they found useful to ask!


Breast Cancer

Lung Cancer

Discover additional accredited CME/CE activities and patient resources on the Virtual Education Hub.

Visit the Hub